Read by QxMD icon Read


Agnieszka Gunia-Krzyżak, Dorota Żelaszczyk, Anna Rapacz, Ewa Żesławska, Anna M Waszkielewicz, Katarzyna Pańczyk, Karolina Słoczyńska, Elżbieta Pękala, Wojciech Nitek, Barbara Filipek, Henryk Marona
A series of twenty two (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH3 or 2-CH3 was designed, synthesized and evaluated for anticonvulsant activity in rodent models of seizures: maximal electroshock (MES) test, subcutaneous pentylenetetrazole (scPTZ) test, and 6-Hz test. There were identified three most active compounds: S-(2E)-N-(1-hydroxypropan-2-yl)-3-(2-methylphenyl)prop-2-enamide (5) (ED50 MES=42.56, ED50 scPTZ=58.38, ED50 6-Hz 44mA=42.27mg/kg tested in mice after intraperitoneal (i...
November 11, 2016: Bioorganic & Medicinal Chemistry
Manish A Parikh, Jonathan Soverow, Martin B Leon, Patrick Serruys, Bo Xu, Zuyi Yuan, Robayaah Zambahari, Ajay Kirtane
AIMS: We assessed long-term outcomes in patients with extra-small (XS) (≤2.25 mm) and small vessels (SV) (>2.25-2.75 mm) treated with the Resolute zotarolimus-eluting stent (R-ZES). METHODS AND RESULTS: Data from eight studies including patients with XS or SV were pooled for this analysis. Among 2,141 patients (837 XS, 1,304 SV), three-year cumulative major adverse cardiac events (15.4% vs. 11.5%; adj. HR [95% CI]: 1.3 [1.0, 1.7], p=0.12), target lesion failure (12...
November 20, 2016: EuroIntervention
Carlo Di Mario, Patrick W Serruys, Sigmund Silber, Shuzheng Lu, Weimin Wang, Petr Widimský, Bo Xu, Stephan Windecker
AIMS: We examined long-term outcomes after implantation of the Resolute zotarolimus-eluting stent (R-ZES) in ST-segment elevation acute myocardial infarction (STEMI) patients. METHODS AND RESULTS: We compared long-term outcomes of STEMI patients undergoing primary angioplasty <12 hours from symptom onset who were randomised to the R-ZES (n=122) or the everolimus-eluting stent (EES, n=158) in the RESOLUTE All Comers Trial after propensity score adjustment. The five-year cumulative incidence of target lesion failure (TLF) was 7...
November 20, 2016: EuroIntervention
Feng Qian, Ye Zhong, Edward L Hannan
OBJECTIVE: First generation paclitaxel-eluting stents (PES) and second generation everolimus-eluting stents (EES) were approved for use in percutaneous coronary interventions (PCIs) in 2004 and 2008, respectively. However, relative long-term outcomes of PES vs EES in real practice remain unclear. We sought to determine the long-term comparative effectiveness of PES vs EES using New York State (NYS) cardiac registries and to assess long-term outcomes of PES vs ZES in six "off-label" and two "high-risk" patient subgroups...
November 2, 2016: International Journal of Cardiology
Sho Torii, Gaku Nakazawa, Takeshi Ijichi, Ayako Yoshikawa, Yohei Ohno, Yuji Ikari
The aim of this study is to evaluate differences in stent endothelial coverage among the second generation of drug-eluting stents. Incomplete stent coverage is one of the major causes of late stent thrombosis. Rabbits fed a normal diet received an everolimus (Xience Prime; EES) and a zotarolimus-eluting stent (Resolute Integrity; R-ZES) in each iliac artery, followed by sacrifice at 14 and 28 days after stent implantation. In addition, a group of atherosclerotic rabbits similarly received EES and R-ZES, and were sacrificed at 28 days...
November 7, 2016: Cardiovascular Intervention and Therapeutics
Ganesh Manoharan, Jorge A Belardi, Zhimin Du, Michael Lee, Shubin Qiao, Patrick W Serruys, Stephan Windecker, Bo Xu, Alan Yeung
AIMS: To investigate whether long-term (3-year) clinical outcomes after multivessel treatment with the Resolute zotarolimus-eluting stent (R-ZES) were similar to single-vessel treatment. METHODS AND RESULTS: The RESOLUTE Global Clinical Trial Program enrolled 7618 patients, of whom 1562 underwent multivessel and 6053 single-vessel treatment with the R- ZES. Patients in the multivessel group were more likely to have complex lesions (58% vs 44%, p<0.001). Clinical outcomes were compared using a Cox regression model adjusted by propensity score to account for differences in baseline characteristics...
October 25, 2016: EuroIntervention
Hirofumi Ohtani, Shigeki Kimura, Tomoyo Sugiyama, Keiichi Hishikari, Toru Misawa, Masafumi Mizusawa, Kazuto Hayasaka, Yosuke Yamakami, Keisuke Kojima, Yuichiro Sagawa, Hiroyuki Hikita, Takashi Ashikaga, Atsushi Takahashi, Mitsuaki Isobe
: Few studies have directly compared vascular responses to second-generation drug-eluting stents (DESs). We performed optical coherence tomography examinations in 56 consecutive patients with implanted single stent [19 cobalt-chromium everolimus-eluting stents (CoCr-EES), 22 platinum-chromium EES (PtCr-EES), and 15 resolute zotarolimus-eluting stents (R-ZES)] for de novo lesions, and who did not have restenosis at their 9-month follow-up. Neointimal thickness (NIT), stent apposition, and neointimal coverage were assessed in every strut...
October 19, 2016: International Journal of Cardiovascular Imaging
Soon Jun Hong, Chul Min Ahn, Byeong-Keuk Kim, Young-Guk Ko, Seung-Ho Hur, Cheol Woong Yu, Seung-Jin Lee, Cheol Ung Choi, Je Sang Kim, Jung-Han Yoon, Young Joon Hong, Jae-Woong Choi, Seung-Hyuk Choi, Yangsoo Jang, Do-Sun Lim
AIMS: At present no proven standard treatment for drug-eluting stent (DES) restenosis is available, and the efficacy and safety of everolimus-eluting stent (EES) and zotarolimus-eluting stent (ZES) for DES restenosis are limited. The purpose of this prospective, randomized 9-month intracoronary ultrasound (IVUS) and 3-year clinical follow-up study was to compare the effects of EESs and ZESs on neointima volume and major adverse cardiovascular events (MACEs) such as death, myocardial infarction (MI), target lesion revascularization (TLR) and stent thrombosis in DES restenosis patients...
September 15, 2016: European Heart Journal
Yuichi Sato, Satoru Hashimoto, Ken-Ichi Mizuno, Manabu Takeuchi, Shuji Terai
Gastrointestinal neuroendocrine tumors (GI-NETs) are rare neoplasms, like all NETs. However, the incidence of GI-NETS has been increasing in recent years. Gastric NETs (G-NETs) and duodenal NETs (D-NETs) are the common types of upper GI-NETs based on tumor location. G-NETs are classified into three distinct subgroups: type I, II, and III. Type I G-NETs, which are the most common subtype (70%-80% of all G-NETs), are associated with chronic atrophic gastritis, including autoimmune gastritis and Helicobacter pylori associated atrophic gastritis...
August 14, 2016: World Journal of Gastroenterology: WJG
Monique Ten Haaf, Yolande Appelman, William Wijns, Gabriel Steg, Laura Mauri, Tessa Rademaker-Havinga, Gwenn Wetzels, Lisa Bousquette, Edoardo Camenzind, Eric Boersma
The prevalence of factors that are associated with an increased risk of stent thrombosis (ST), including smoking, diabetes mellitus, and small stent size, is different in women and men who underwent percutaneous coronary intervention. Thus, gender may potentially modify the relation between stent type and the incidence of ST during long-term follow-up. We explored the data of Patient Related Outcomes With Endeavor Versus Cypher stenting Trial (PROTECT) to evaluate this hypothesis. PROTECT randomized 2,061 women and 6,648 men who underwent percutaneous coronary intervention for various indications to Endeavor zotarolimus-eluting stenting (E-ZES) or Cypher sirolimus-eluting stenting (C-SES)...
October 15, 2016: American Journal of Cardiology
Lauren Linder, Cynthia Tamboue, Jennifer N Clements
OBJECTIVE: To review primary literature of gastric acid suppressive agents and vitamin B12 deficiency. DATA SYNTHESIS: From the published articles, proton pump inhibitors (PPIs) are associated with a higher risk of inducing vitamin B12 deficiency than histamine-2 receptor antagonists (H2RAs). Literature suggests that there is an increased risk of developing vitamin B12 deficiency in patients who are exposed to extended durations of therapy with PPIs. There are, however, some conflicting data in elderly patients suggesting that the PPI use for more than 3 years does not increase the risk of vitamin B12 deficiency...
August 12, 2016: Journal of Pharmacy Practice
Alessandro Durante, Giovanni Foglia Manzillo, Francesco Burzotta, Carlo Trani, Cristina Aurigemma, Francesco Summaria, Roberto Patrizi, Giovanni Paolo Talarico, Azeem Latib, Filippo Figini, Enrico Romagnoli, Mariarosaria De Vita, Cecilia Fantoni, Luigi My, Claudio Larosa, Alessandro Manzoli, Maurizio Turturo, Andrea Berni, Giovanni Corrado
BACKGROUND: Diffuse coronary artery disease treatment still remains a challenge for interventional cardiologists and cardiac surgeons. There are few data on full metal jacket (FMJ) stenting, especially with new-generation drug-eluting stents. We aimed to assess the efficacy and safety of FMJ with new-generation Zotarolimus-eluting stents (n-ZES). METHODS AND RESULTS: All patients who underwent FMJ with n-ZES (≥60mm stent length) in eleven Italian interventional centers participating in the Clinical Service® project were included in this analysis...
October 15, 2016: International Journal of Cardiology
Kenji Kawai, Minoru Ichikawa, Tohru Masuyama, Yoshiyuki Kijima
BACKGROUND: Arterial repair after intracoronary stenting depends on stent types and plaque vulnerability. The aim of this study was angioscopic comparison of arterial repair after implantation of the second-generation drug-eluting stents (G2-DES) between the stable and vulnerable plaques. METHODS: Four types of G2-DES were successfully implanted into stable plaques (n=41) and vulnerable plaques (n=34): 13 and 9 Xience-everolimus-, 7 and 6 Endeavor-zotarolimus-, 15 and 9 Resolute-zotarolimus-, and 6 and 10 Nobori-biolimus-eluting stents (EES, E-ZES, R-ZES, and BES), respectively...
October 15, 2016: International Journal of Cardiology
Zarrin Sarhadynejad, Fariba Sharififar, Abbas Pardakhty, Mohammad-Hadi Nematollahi, Saeedeh Sattaie-Mokhtari, Ali Mandegary
ETHNOPHARMACOLOGICAL RELEVANCE: "Zereshk-e-Saghir" (ZES), one of the traditional herbal medicines in old manuscripts of Persian hakims, has been used for the treatment of liver disorders. This current study is aimed to evaluate ZES effects on animal model to investigate its safety and hepatoprotective activity. MATERIALS AND METHODS: ZES was prepared according to a traditional method by blending aqueous extracts of Berberis vulgaris L., with fine particles of other plants including Rosa damascene Mill, Cichorium intybus L...
August 22, 2016: Journal of Ethnopharmacology
Milosz Jaguszewski, Manuela Dörig, Antonio H Frangieh, Jelena-Rima Ghadri, Victoria Lucia Cammann, Johanna Diekmann, L Christian Napp, Fabrizio D'Ascenzo, Yoichi Imori, Slayman Obeid, Willibald Maier, Thomas F Lüscher, Christian Templin
BACKGROUND: Comparative data on long-term safety and efficacy of bioresorbable-polymer-BES versus durable-polymer-EES/ZES in ACS setting have hitherto been lacking. We sought to assess the safety and efficacy of bioresorbable-polymer-biolimus-A9-eluting stents (BES) compared with thin-strut-durable-polymer-everolimus- and zotarolimus-eluting stents (EES/ZES) in patients with acute coronary syndrome (ACS) undergoing PCI. METHODS AND RESULTS: Between 2007 and 2012, 1,547 patients were implanted with new-generation drug-eluting stents (DES)...
July 5, 2016: Catheterization and Cardiovascular Interventions
Hee Eun Lee, Taofic Mounajjed, Lori A Erickson, Tsung-Teh Wu
Well-differentiated neuroendocrine tumor (WDNET) of the stomach can arise in three distinct clinical settings: (1) in association with autoimmune atrophic gastritis, (2) in association with multiple neuroendocrine neoplasia type I (MEN I) or Zollinger-Ellison syndrome (ZES), or (3) sporadic. The Ki-67 proliferative index (PI) in gastric WDNETs in these three distinct clinical settings has not been evaluated in detail. Forty-five gastric WNETs underwent polypectomy (n = 4), endoscopic mucosal resection (n = 12), and surgical resection (n = 29) between 1994 and 2015 were included...
September 2016: Endocrine Pathology
Mohamad J Alshikho, Salem I Noureldine, Joud M Talas, Antoine Nasimian, Safi Zazou, Bashir Mobaed, Mahmoud Nasser
BACKGROUND: Pancreatic endocrine tumors (PETs) are rare and can occur as part of neurofibromatosis type 1 (NF1). Gastrinomas are functional PETs that are rarely associated with NF1. Only two cases of their occurrence have been reported in the literature. CASE REPORT: A 28-year-old woman was admitted for further evaluation of epigastric soreness, heartburn, nausea, vomiting, diarrhea, and a significant weight loss. Physical examination was remarkable for cutaneous findings (axillary freckling and multiple café-au-lait spots) as well as neurofibromas (dermal, plexiform)...
2016: American Journal of Case Reports
Saami K Yazdani, Alexander Sheehy, Stephen Pacetti, Brandon Rittlemeyer, Frank D Kolodgie, Renu Virmani
BACKGROUND: Coatings consisting of a polymer and drug are widely used in drug-eluting stents (DES) and are essential in providing programmable drug release kinetics. Among other factors, stent coating technologies can influence blood compatibility, affect acute and sub-acute healing, and potentially trigger a chronic inflammatory response. OBJECTIVE: The aim of this study was to investigate the short-term (7 and 28 days) and long-term (90 and 180 days) coating integrity of the Xience Prime Everolimus-Eluting Stent (EES), Resolute Zotarolimus-Eluting Stent (ZES), Taxus Paclitaxel-Eluting Stent (PES), and Nobori Biolimus A9-Eluting Stent (BES) in a rabbit ilio-femoral stent model...
June 10, 2016: Journal of Interventional Cardiology
Si-Hyuck Kang, In-Ho Chae, Jin-Joo Park, Hak Seung Lee, Do-Yoon Kang, Seung-Sik Hwang, Tae-Jin Youn, Hyo-Soo Kim
OBJECTIVES: This study sought to perform a systematic review and network meta-analysis to compare the relative safety and efficacy of contemporary DES and BVS. BACKGROUND: To improve outcomes of patients undergoing percutaneous coronary revascularization, there have been advances in the design of drug-eluting stents (DES), including the development of drug-eluting bioresorbable vascular scaffolds (BVS). METHODS: Prospective, randomized, controlled trials comparing bare-metal stents (BMS), paclitaxel-eluting stents (PES), sirolimus-eluting stents (SES), Endeavor zotarolimus-eluting stents (E-ZES), cobalt-chromium (CoCr) everolimus-eluting stents (EES), platinum-chromium (PtCr)-EES, biodegradable polymer (BP)-EES, Resolute zotarolimus-eluting stents (R-ZES), BP biolimus-eluting stents (BP-BES), hybrid sirolimus-eluting stents (H [Orsiro]-SES), polymer-free sirolimus- and probucol-eluting stents, or BVS were searched in online databases...
June 27, 2016: JACC. Cardiovascular Interventions
Elisabeth Hain, Romain Coriat, Bertrand Dousset, Sébastien Gaujoux
Gastrinoma is a very rare tumor leading to gastrin hypersecretion and characterised by Zollinger-Ellisson syndrome (ZES) i.e. severe gastric and duodenal ulceration and profuse diarrhea. This disease can be sporadic or familial within a multiple endocrine neoplasia type 1 (MEN-1) syndrome. Diagnosis is based on hypergastrinemia/hypercholrhydria. Tumors are usually located in the duodeno-pancreas. Preoperative tumor location by CT, echoendoscopy and fibroscopy is not always possible because of the small size of the lesion that are frequently multiple...
June 1, 2016: La Presse Médicale
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"